Cash, cash equivalents and marketable securities as of March 31, 2024 were $201.9 million. The Company anticipates that its existing cash, cash equivalents and marketable securities will fund Prelude’s operations into 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRLD:
- Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Prelude Therapeutics participates in a conference call with JMP Securities
- Prelude Therapeutics Announces CFO Transition and Interim Appointment
- Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
- Prelude Therapeutics initiated with an Outperform at JMP Securities